share_log

大行评级|美银:下调中生制药目标价至3.6港元 维持“买入”评级

Bank Rating | Bank of America: Lowering the target price of Zhongsheng Pharmaceuticals to HK$3.6 to maintain a “buy” rating

Gelonghui Finance ·  Apr 2 16:34
Glonghui, April 2 | Bank of America Securities issued a report lowering the sales expenses forecast for Zhongsheng Pharmaceuticals this year and beyond to reflect the Group's progress in cost control, while increasing the Group's R&D cost forecast for this year and beyond to reflect the Group's increasing investment in innovative products. According to the report, since Zhongsheng Pharmaceutical sold 67% of Chia Tai Qingdao's shares to Guoxin Group, the target price of Zhongsheng Pharmaceuticals was lowered from HK$4.2 to HK$3.6, but maintained a “buy” rating to reflect the group's transition to innovative products. The total number of innovative and biosimilar products is expected to reach 15 this year and further increase to 20 by 2025.

The translation is provided by third-party software.


The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment